Related to Pharming Spins Out 49% of DNage Subsidiary Back to Its Original Shareholders

• Biogen Idec Takes Over Development of Hemophilia Therapies in Deal with Swedish Orphan Biovitrum
  
• Swedish Orphan Taps Biomodels to Develop Screening Platform for Oral Mucositis Risk
  
• Sigma-Tau Makes $5M Cash Payment and Equity Investment to Develop Dyax' HAE Drug
  
• Swedish Orphan Biovitrum and Dongbao Ink Deal for European and Chinese Markets
  
• CMIC Pays Dyax $4M Up Front to Develop and Commercialize HAE Therapy in Japan
  
• Shire Reports Positive Phase III Icatibant Data to Address Nonapprovable Status in U.S.
  
• SOBI to Distribute Fresenius’ EU-Approved Malignant Ascites Drug in 15 Euro Countries
  
• ViroPharma Licenses Halozyme’s Hyaluronidase for $9M to Develop Subcutaneous Cinryze
  
• Defiante Takes Over Additional Territories for Marketing Dyax' HAE Drug
  
• Renova to Develop Transgenic Rabbits for Pharming’s Recombinant FVIII Program
  
• Sobi, Affibody Partner on IL-1 Anti-Inflammatories
  
• Firms Project 2013 BLA for Long-Acting Hemophilia A Therapy
  
• Merger Terminated between Presidio and BioCryst
  
• BioCryst Halves Staff After Setbacks
  
• Dyax Makes Latin American HAE Drug Deal
  
• Pharming Obtains Roughly $10.82M to Progress Regulatory Review of Its Hereditary Angioedema Treatment
  
• Pharming Sharpens Ax as Layoffs Loom
  
• Pharming Earns $15M Up Front as Part of Deal with Santarus for HAE Drug
  
• FDA Refuses to File Pharming's BLA for EU-Approved HAE Therapy
  
• Swedish Orphan Nabs 10-Year Distribution Rights to Pharming’s HAE Therapy in Europe